文章名稱引用次數(shù)

• Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up50
• Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals28
• Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study25
• Surgical trends in breast cancer: a rise in novel operative treatment options over a 12year analysis22
• Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-201022
• Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review20
• Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial19
• Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study18
• Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer18
• MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis17